How To Use A Pepsy

Transcription

1 Technology Offer Summary Use of VIP (Vasoactive intestinal peptide ) as a prognostic marker of autoimmune diseases A Spanish research group in collaboration with a hospital biomedical research institute, have identified that having low VIP serum levels is a biomarker of worse clinical course and higher requirements of treatment in patients with early Rheumatoid arthritis and Spondyloarthritis. This improves the predictive value of ACPA (anti-citrullinated protein antibodies), and the related treatment. They are looking for biopharmaceutical companies for licensing or joint venture agreement. Expiration Date 13 February 2017 Reference TOES Profile link Details Description The Spanish research group in collaboration with a hospital biomedical research institute have discovered a biomarker that identifies early stages of RA and Spa, Rheumatoid arthritis (RA) and Spondyloarthritis (Spa) are autoimmune disorders that can lead to severe disability and increased mortality. Early intensive immunomodulatory treatment is the best approach to slow progression and change long-term outcome. However, it is important to detect those patients who are destined to have a more benign disease to avoid over-treating them. Probably the only validated prognostic factor in RA is anti-citrullinated protein antibodies (ACPA). There are no validated biomarkers for Spa and other autoimmune disorders. The research group has described that having low VIP serum levels is a biomarker of worse clinical course and higher requirements of treatment in patients with early RA and Spa the relevance of this new biomarker is that it improves the predictive value of ACPA since detect ACPA negative patients at risk of poor evolution and those with both biomarkers exhibited higher requirements of treatment. VIP has been involved in the differentiation of Th lymphocytes decreasing the production of proinflammatory mediators and administration of exogenous VIP ameliorates arthritis in murine models. It is likely that those patients who are unable to up-regulate their VIP levels when they develop RA, show a worse clinical course. They are looking for biopharmaceutical companies interested in licensing the technology of for joint venture agreement. These partnership are the most suitable for them as their developments cannot go further and need a partner to jointly continue with it, or interested in license in the development to introduce it into their portfolio and develop it. Advantages and Innovations Ref: TOES Page 1 of 3 Printed: 06 September 2016

2 The main advantage is that by the administration of this product, it could be possible to diagnose patients to a more intense treatment at first stages. This implies a clear save of costs, as in some of the patients early diagnosed an overtreatment can be avoided. Prevents progression of RA and Spa, as they are identified in early stages. Stage of Development Field tested/evaluated Keywords Technology Diagnostics, Diagnosis Biochemistry / Biophysics Market Diagnostic services Molecular diagnosis NACE M Q Research and experimental development on biotechnology Hospital activities Open for EOI : Yes Client Type and Size of Organisation Behind the Profile R&D Institution Year Established 0 Client Country Spain Partner Sought Ref: TOES Page 2 of 3 Printed: 06 September 2016

3 Type and Role of Partner Sought Biopharmaceutical company that want to quickly expand the patent portfolio, related with diagnostics on autoimmune diseases. The research group could develop further innovations for the biopharmaceutical company if the agreement is as joint venture. Type and Size of Partner Sought SME 11-50,University,Inventor,R&D Institution,SME <10,>500 MNE, ,SME ,>500 Type of Partnership Considered License agreement Joint venture agreement Ref: TOES Page 3 of 3 Printed: 06 September 2016

4 Technology Offer Novel plasmid and its construction, novel bacterial strains, their application and methods for the production of carotenoids Summary A Polish university has developed an invention which comprises the construction and usage of a specific plasmid for the creation of novel bacterial strains that are able to efficiently produce of various types of carotenoid. The invention has been filed with the Polish Patent Office and is in Patent Cooperation Treaty phase. The university is looking for cooperation under license, manufacturing or research agreements. Expiration Date 29 January 2017 Reference TOPL Profile link Details Description A Polish university has developed an invention which comprises the construction and usage of specific plasmid for the creation of novel bacterial strains able to efficient production of various carotenoids. Obtained plasmid is stably maintained in bacterial culture. Using the specific plasmid two carotenoids-producing strains (Paracoccus aminophilus KKP 2053p i Paracoccus kondratievae KKP 2054p) were obtained. Both strains are also included within the invention. They can be fast and easily cultivated, using various media. The invention has been filed to Polish Patent Office and in Patent Cooperation Treaty phase. University is looking for cooperation under license, manufacturing or research agreement. Advantages and Innovations Specific Plasmid is a mobile genetic platform enabling the production of carotenoids it s a mobilizable vector, so it can be easily introduced by conjugation to a variety of bacterial hosts (belonging to the family Enterobacteriaceae and class Alphaproteobacteria). Plasmid is stably maintained in bacterial culture. It has a system to eliminate the plasmid-less cells. It is stably maintained in a bacterial population at 100% cells even after 120 generations of growth, and therefore it can be used even without the antibiotic pressure, which reduces the cost of the producing of carotenoid pigments. The carotenoid production by obtained strains P. kondratievae KKP 2054p and P. aminophilus KKP 2053p is efficient and cheap. The process of extraction carotenoid pigments from the bacterial cells is relatively easy, and above all very efficient (e.g. compared to extraction from plant tissues). Chemical analyses revealed that the strain KKP 2053p is producing mainly β-carotene (nearly homogenic fraction, free of its α and γ derivatives). The strain KKP 2054p is producing both Ref: TOPL Page 1 of 3 Printed: 31 August 2016

5 xanthophylls (including astaxanthin, adonixanthin, adonirubin and canthaxanthin) and carotenes (including echinenone, hydroxyechinenone and β-carotene). The production of carotenoids is efficient and amounts to (+/- 138) µg / 1 g dry weigh for the strain KKP 2053p and (+/- 10) µg / 1 g dry weigh for the strain KKP 2054p. Stage of Development Under development/lab tested Keywords Technology Genetic Engineering Microbiology Market Genetic Engineering Microbiology NACE M P Other professional, scientific and technical activities n.e.c. Tertiary education Open for EOI : Yes Client Type and Size of Organisation Behind the Profile University Year Established 1816 Client Country Poland Partner Sought Ref: TOPL Page 2 of 3 Printed: 31 August 2016

6 Type and Role of Partner Sought The type of Partner Sought: industry, R&D institutions, The tasks to be performed by the partner sought: joint research/licensing and development of the invention. Type and Size of Partner Sought University,R&D Institution,>500 MNE, ,SME ,>500 Type of Partnership Considered License agreement Manufacturing agreement Research cooperation agreement Ref: TOPL Page 3 of 3 Printed: 31 August 2016